HER2 mutations occur in 2–4% of cases, and amplifications in 1–3% [5, 6] Mutations in the HER2 (ERBB2) gene define a distinct molecular subtype of lung cancer, primarily found in adenocarcinomas, with higher prevalence among women and non-smokers. This evidence concerns the gene ERBB2 and adenocarcinoma.